Julia Aijun Wang
CIK 1860279 · Chief Financial Officer, EVP · last filed 2026-02-13
Julia Aijun Wang is a Chief Financial Officer, EVP who has filed 29 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for LH, was dated Feb 13, 2026. Across all open-market trades the lifetime net is −$1.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $655.7K across reported positions. 24 SEC filings were submitted jointly with BeiGene, Ltd.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BGNE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BURLINGTON, NC 27215
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LH | Chief Financial Officer, EVP | 2,062 | $317.95 | $655.7K | $0 | 6 | 2026-02-13 |
| BeOne Medicines Ltd. (BGNE) Delisted | Chief Financial Officer | 0 | $184.71 | $0 | -$1.00M | 15 | 2024-07-03 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-13 | LH | Mixed | +615 | -$71.0K | EDGAR |
| 2026-02-12 | LH | Grant (A) | — | $0 | EDGAR |
| 2026-02-10 | LH | Mixed | +639 | -$70.4K | EDGAR |
| 2025-02-13 | LH | Grant (A) | — | $0 | EDGAR |
| 2025-02-10 | LH | Mixed | +557 | -$83.2K | EDGAR |
| 2024-12-04 | LH | Grant (A) | — | $0 | EDGAR |
| 2024-09-03 | — | Notice (144) | −3,160 | -$600.7K | EDGAR |
| 2024-07-03 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −472 | -$67.9K | EDGAR |
| 2024-07-01 | — | Notice (144) | −472 | -$67.9K | EDGAR |
| 2024-06-26 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −899 | -$139.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.